[go: up one dir, main page]

NO20053119L - Farmasoytiske sarmmensetninger med fentanyl for intranasal administrasjon. - Google Patents

Farmasoytiske sarmmensetninger med fentanyl for intranasal administrasjon.

Info

Publication number
NO20053119L
NO20053119L NO20053119A NO20053119A NO20053119L NO 20053119 L NO20053119 L NO 20053119L NO 20053119 A NO20053119 A NO 20053119A NO 20053119 A NO20053119 A NO 20053119A NO 20053119 L NO20053119 L NO 20053119L
Authority
NO
Norway
Prior art keywords
fentanyl
same
intranasal administration
pharmaceutically acceptable
aqueous solution
Prior art date
Application number
NO20053119A
Other languages
English (en)
Other versions
NO335127B1 (no
NO20053119D0 (no
Inventor
Peter James Watts
Jonathan David Castile
William Columbus Ian Lafferty
Alan Smith
Original Assignee
Archimedes Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9950919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20053119(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Archimedes Dev Ltd filed Critical Archimedes Dev Ltd
Publication of NO20053119D0 publication Critical patent/NO20053119D0/no
Publication of NO20053119L publication Critical patent/NO20053119L/no
Publication of NO335127B1 publication Critical patent/NO335127B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Blanding for intranasal tilførsel av fentanyl eller et farmasøytisk akseptabelt salt av samme til et dyr, omfattende en vannbasert løsning av (i) fentanyl eller et farmasøytisk akseptabelt salt av samme, og (i i) et farmasøytisk akseptabelt additiv valgt fra (a) pektin, og (b) en poloksamer og kitosan eller et salt eller derivat av samme, forutsatt at blandingen er hovedsakelig fri for divalente metallioner når blandingen omfatter et pektin, og som sammenliknet med en enkel vannbasert løsning av fentanyl administrert intranasalt ved samme dose, framskaffer en maksimal plasmakonsentrasjon av fentanyl (Cmax) fra 10 til 80% av det som oppnås ved bruk av en enkel vannbasert løsning av fentanyl administrert intranasalt ved en identisk fentanyldose.
NO20053119A 2003-01-10 2005-06-24 Blanding for intranasal tilførsel av fentanyl, anvendelse av et pektin, en sprayanordning og en fremgangsmåte for framstilling av blandingen. NO335127B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0300531.1A GB0300531D0 (en) 2003-01-10 2003-01-10 Pharmaceutical compositions
PCT/GB2004/000057 WO2004062561A2 (en) 2003-01-10 2004-01-12 Pharmaceutical compositions comprising fentanyl for intranasal delivery

Publications (3)

Publication Number Publication Date
NO20053119D0 NO20053119D0 (no) 2005-06-24
NO20053119L true NO20053119L (no) 2005-08-03
NO335127B1 NO335127B1 (no) 2014-09-22

Family

ID=9950919

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053119A NO335127B1 (no) 2003-01-10 2005-06-24 Blanding for intranasal tilførsel av fentanyl, anvendelse av et pektin, en sprayanordning og en fremgangsmåte for framstilling av blandingen.

Country Status (25)

Country Link
US (5) US20040166067A1 (no)
EP (2) EP1635783B1 (no)
JP (1) JP4827725B2 (no)
KR (3) KR20100118144A (no)
CN (1) CN100423709C (no)
AU (1) AU2004204381B2 (no)
BR (1) BRPI0406674B8 (no)
CA (1) CA2511974C (no)
CY (1) CY1115056T1 (no)
DK (1) DK1635783T5 (no)
EA (1) EA008500B1 (no)
ES (2) ES2432119T3 (no)
FR (1) FR14C0020I1 (no)
GB (1) GB0300531D0 (no)
GE (1) GEP20084340B (no)
IL (1) IL169480A (no)
MX (1) MXPA05007333A (no)
NO (1) NO335127B1 (no)
NZ (1) NZ541018A (no)
PL (1) PL212950B1 (no)
PT (2) PT1635783E (no)
SI (1) SI1635783T1 (no)
UA (1) UA85050C2 (no)
WO (1) WO2004062561A2 (no)
ZA (1) ZA200505274B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001281746C1 (en) * 2000-07-31 2010-09-09 ISTITUTO GENTILI S.r.l. Fentanyl composition for nasal administration
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US20050129679A1 (en) 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
EP2057982A1 (en) 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
GB2464282A (en) * 2008-10-08 2010-04-14 Archimedes Dev Ltd A device for administering a dose of opioid analgesic
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
HUE030896T2 (en) 2011-02-04 2017-06-28 Archimedes Dev Ltd Improved tank
CN107260672A (zh) 2011-05-13 2017-10-20 欧洲凯尔特公司 包含纳洛酮的鼻内药物剂型
CA2886270C (en) 2012-10-03 2020-04-07 Proponent Biotech Gmbh Esters of short chains fatty acids for use in the treatment of immunogenic disorders
AU2014317035B2 (en) 2013-09-05 2020-02-27 Ab2 Bio Sa IL-18 binding protein (IL-18BP) in inflammatory diseases
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
SG11201706879UA (en) 2015-03-05 2017-09-28 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
WO2018130948A1 (en) * 2017-01-11 2018-07-19 Torrent Pharmaceuticals Limited Tapentadol nasal composition
US11207309B2 (en) 2019-07-19 2021-12-28 Hikma Pharmaceuticals International Limited Ready-to-administer fentanyl formulations
US11160799B2 (en) * 2019-10-22 2021-11-02 Cessatech A/S Pediatric combination
CN111272860B (zh) 2020-03-16 2022-11-25 中国检验检疫科学研究院 一种芬太尼类物质的小型便携式质谱现场快速检测方法
US20230173021A1 (en) 2020-05-06 2023-06-08 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) In Respiratory Diseases
GB202007404D0 (en) 2020-05-19 2020-07-01 Nasser Syed Muhammad Tahir Treatment for viral respiratory infections
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
WO2023067348A1 (en) 2021-10-21 2023-04-27 Biosirius Ltd Treatment for virally-induced pneumonia
EP4486367A1 (en) 2022-03-04 2025-01-08 AB2 Bio SA Il-18 binding protein (il-18bp) in the treatment of vexas

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2125212A (en) * 1938-05-03 1938-07-26 Vick Chemical Company Therapeutic composition
US2730483A (en) * 1952-08-12 1956-01-10 Nepera Chemical Co Inc Therapeutic compositions comprising neomycin, gramicidin and quaternary ammonium salt of thonzylamine
NL135583C (no) * 1961-10-10
US3184600A (en) 1963-05-07 1965-05-18 Potter Instrument Co Inc Photosensitive apparatus for measuring coordinate distances
JPS5885813A (ja) * 1981-11-17 1983-05-23 Toyo Jozo Co Ltd 吸収性良好な製剤
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4486423A (en) * 1983-04-21 1984-12-04 Janssen Pharmaceutica Inc. Stable fentanyl composition
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5122127A (en) 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
HU193780B (en) * 1985-06-21 1987-11-30 Richter Gedeon Vegyeszet Process for producing 2-halogeno-6-methyl-ergol-9-ene derivatives and acid additional salts thereof
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPS62123112A (ja) * 1985-11-22 1987-06-04 Sunstar Inc 軟膏基剤
DE3601132A1 (de) 1986-01-16 1987-07-23 Christian Bannert Verfahren zur behandlung der schleimhaut
JPS62236862A (ja) 1986-04-09 1987-10-16 Nippon Kayaku Co Ltd 人工粘液
ZA875317B (en) 1986-08-01 1988-01-25 Warner-Lambert Company Transdermal compositions
DE3779999T2 (de) 1986-11-14 1992-12-10 Theratech Inc Erhoehung des penetrationsvermoegens mittels eines aus die zellhuelle veraendernden substanzen und kurzkettigen alkoholen bestehenden binaeren systems.
US4826683A (en) * 1987-01-09 1989-05-02 Bates Harry L Decongestant
US5200180A (en) * 1987-06-26 1993-04-06 Christian Bannert Pharmaceutical composition for the treatment of the human eye
DE3726797A1 (de) * 1987-08-12 1989-02-23 Bayer Ag Arzneimittel fuer den bereich der mundhoehle
US4915948A (en) * 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
DE3827561C1 (no) * 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
GB8900267D0 (en) 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
GB2237510B (en) 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
NL9000634A (nl) 1990-03-20 1991-10-16 Catharina Ziekenhuis Stichting Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding.
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
US5346703A (en) * 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
EP0491076A1 (en) 1990-12-19 1992-06-24 Theratech, Inc. Penetration enhancement with multi-component system of N-aliphatic pyrrolidones with lower alcohols
JPH0597706A (ja) 1991-04-09 1993-04-20 Chemex Block Drug Jv アフタ性潰瘍および他の粘膜皮膚障害の処置方法
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
ATE158172T1 (de) 1992-05-26 1997-10-15 Procter & Gamble Pulverförmige pharmazeutische zusammensetzung
EP0651993B1 (en) 1992-07-23 2002-10-09 Hisamitsu Pharmaceutical Co., Inc. Percutaneously administrable base composition and drug composition prepared therefrom
WO1994010987A1 (en) 1992-11-09 1994-05-26 Pharmetrix Corporation Combined analgesic delivery methods for pain management
US5507277A (en) * 1993-01-29 1996-04-16 Aradigm Corporation Lockout device for controlled release of drug from patient-activateddispenser
EP0689438B1 (en) 1993-03-26 2003-06-04 Franciscus Wilhelmus Henricus Maria Merkus Pharmaceutical compositions for intranasal administration of apomorphine
GB9310412D0 (en) 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
SE9301877D0 (sv) 1993-06-02 1993-06-02 Kabi Pharmacia Ab In situ gel for therapeutic use
CA2167081A1 (en) 1993-07-12 1995-01-26 Alexander K. Andrianov Hydrogel microencapsulated vaccines
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
GB9406171D0 (en) * 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
WO1995026715A2 (en) * 1994-03-30 1995-10-12 Dumex-Alpharma A/S Use of fatty acid esters as bioadhesive substances
AU2266995A (en) 1994-04-21 1995-11-16 Hisamitsu Pharmaceutical Co., Inc. Percutaneously administrable base composition and percutaneously administrable drug composition prepared therefrom
EP0759744B1 (en) * 1994-05-13 2001-10-17 Aradigm Corporation Narcotic containing aerosol formulation
GB9414966D0 (en) 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
FR2733420B1 (fr) 1995-04-28 1997-06-27 Sep Tarral Preparations pectiques utilisables comme support de medicament
ZA964320B (en) 1995-06-05 1997-01-13 Alza Corp Device for transdermal electrotransport delivery of fentanyl and sufentanil
AU699774B2 (en) 1995-06-05 1998-12-17 Alza Corporation Device for transdermal electrotransport delivery of fentanyl and sufentanil
US6881208B1 (en) 1995-06-05 2005-04-19 Joseph B. Phipps Method and device for transdermal electrotransport delivery of fentanyl and sufentanil
JP3098401B2 (ja) 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
DE19527411A1 (de) * 1995-07-27 1997-01-30 Ackermann & Schmitt Gmbh & Co Kupplung
US5840731A (en) 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
IL127955A0 (en) 1996-07-11 1999-11-30 Farmarc Nederland Bv Pharmaceutical composition containing acid addition salt of basic drug
US6667279B1 (en) 1996-11-13 2003-12-23 Wallace, Inc. Method and composition for forming water impermeable barrier
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
GB2328443B (en) 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
AU751182B2 (en) 1997-12-02 2002-08-08 Archimedes Development Limited Compositions for nasal administration
US6090368A (en) 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
CA2341732C (en) 1998-08-26 2008-08-19 Teijin Limited Powder composition for nasal administration
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
GB9823246D0 (en) 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
JP2000229859A (ja) 1999-02-12 2000-08-22 Teijin Ltd 安定なブプレノルフィン経鼻製剤
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
US6541021B1 (en) 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
JP2001002589A (ja) 1999-06-18 2001-01-09 Teijin Ltd 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物
DE60044134D1 (de) * 1999-08-26 2010-05-20 Takeda Pharmaceutical Nasenschleimhaut haftende matrix
JP2001089359A (ja) 1999-09-24 2001-04-03 Toko Yakuhin Kogyo Kk 鎮痛成分の点鼻用ゲルまたはゾル製剤
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
SI1299104T1 (sl) 2000-02-08 2009-10-31 Euro Celtique Sa Oralne formulacije opioidnih agonistov, varne pred zlorabo
AU4341401A (en) 2000-03-10 2001-09-24 Durect Corp Opioid formulations
AU2001262992A1 (en) 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US6610271B2 (en) 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
WO2001097780A2 (en) 2000-06-22 2001-12-27 Pharmasol Ltd Pharmaceutical compositions comprising an opioid analgesic
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
AU2001281746C1 (en) 2000-07-31 2010-09-09 ISTITUTO GENTILI S.r.l. Fentanyl composition for nasal administration
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
GB2378383A (en) 2001-06-06 2003-02-12 Gursharan Moonga Nasal delivery of pharmaceutical compositions in powder form
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
US20120277267A1 (en) 2012-11-01
CN100423709C (zh) 2008-10-08
GEP20084340B (en) 2008-03-25
US20080153879A1 (en) 2008-06-26
HK1088555A1 (en) 2006-11-10
NO335127B1 (no) 2014-09-22
PL377823A1 (pl) 2006-02-20
BRPI0406674B1 (pt) 2015-12-22
SI1635783T1 (sl) 2013-11-29
PL212950B1 (pl) 2012-12-31
BRPI0406674B8 (pt) 2021-05-25
US20040166067A1 (en) 2004-08-26
EP1635783B1 (en) 2013-09-18
CA2511974A1 (en) 2004-07-29
EP1635783A2 (en) 2006-03-22
US9814705B2 (en) 2017-11-14
PT1635783E (pt) 2013-10-29
FR14C0020I1 (fr) 2014-04-18
CY1115056T1 (el) 2016-12-14
US20120270903A1 (en) 2012-10-25
NO20053119D0 (no) 2005-06-24
GB0300531D0 (en) 2003-02-12
AU2004204381A2 (en) 2004-07-29
IL169480A (en) 2013-10-31
DK1635783T5 (da) 2014-05-12
KR20100118144A (ko) 2010-11-04
US9078814B2 (en) 2015-07-14
NZ541018A (en) 2008-07-31
CN1723012A (zh) 2006-01-18
KR20050103275A (ko) 2005-10-28
CA2511974C (en) 2011-03-01
EA008500B1 (ru) 2007-06-29
IL169480A0 (en) 2007-07-04
MXPA05007333A (es) 2006-02-17
EP2436375A1 (en) 2012-04-04
EP2436375B1 (en) 2019-02-27
DK1635783T3 (da) 2013-10-14
JP4827725B2 (ja) 2011-11-30
UA85050C2 (ru) 2008-12-25
PT2436375T (pt) 2019-05-24
ZA200505274B (en) 2014-09-25
JP2006516272A (ja) 2006-06-29
US20150283123A1 (en) 2015-10-08
ES2432119T3 (es) 2013-11-29
AU2004204381A1 (en) 2004-07-29
KR20090058596A (ko) 2009-06-09
WO2004062561A2 (en) 2004-07-29
AU2004204381B2 (en) 2010-11-25
WO2004062561A3 (en) 2004-10-07
ES2721899T3 (es) 2019-08-06
US8216604B2 (en) 2012-07-10
EA200501105A1 (ru) 2005-12-29
KR101012148B1 (ko) 2011-02-07
US8889176B2 (en) 2014-11-18
BRPI0406674A (pt) 2005-12-20

Similar Documents

Publication Publication Date Title
NO20053119L (no) Farmasoytiske sarmmensetninger med fentanyl for intranasal administrasjon.
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
ZA202307575B (en) Methods and modified nucleosides for treating coronavirus infections
NO20063411L (no) Fremgangsmater og doseringsformer for okt opploselighet av legemiddelbestanddeler for kontrollert frigiving
DK1341542T3 (da) Indanylderivater til behandling af luftvejssygdomme
DK1207756T3 (da) Anvendelse af spinosad eller en formulering, der omfatter spinosad
NO20052019L (no) Blanding for a inhibere sekresjon av magesyre
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
NO20061840L (no) Legemiddelbelegg som tilveiebringer hoy legemiddeltilsetning og fremgangsmater for a tilveiebringe samme
WO2005069933A3 (en) Methods of treating an inflammatory-related disease
CY1107096T1 (el) Μεθοδοι και φαρμακοτεχνικες μορφες ελεγχομενης απελευθερωσης παλιπεριδονης
NO20045072L (no) Tablett med hoyt medikamentinnhold
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
NO20092254L (no) Pulverformuleringer for valganciclovir
EA200500985A1 (ru) Твердая лекарственная форма для перорального применения
NO20062051L (no) Farmasoytisk virkestoffinneholdende formulering med belegg
DK1678162T3 (da) P-glycoprotein-inhibitor, fremgangsmåde til fremstilling heraf og farmaceutisk sammensætning omfattende denne
NO20051670L (no) Formuleringer som omfatter en indolinonforbindelse
NO20044810L (no) Farmasoytisk formulering med oyeblikkelig frigjoring
TW200420554A (en) A intra-airway administrating preparation
NO20061702L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist
CY1112057T1 (el) Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι
SI1750703T1 (sl) Postopek za zmanjšanje gastrointestinalne toksičnosti zaradi dajanja tegafurja
NO20051463L (no) Inhaleringssammensetninger med hoy legemiddelandel
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: KYOWA KIRIN SERVICES LTD., GB

MK1K Patent expired